Page 5 - பத்தியில் உயிர் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Passage Bio, Inc S-3ASR Mar 5, 2021 5:22 PM
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Amgen Inc (NASDAQ:AMGN) - The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Axsome Therapeutics Inc (NASDAQ: AXSM) (before the market open)
Amicus Therapeutics, Inc. (NASDAQ: FOLD) (before the market open)
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) (before the market open)
Athenex Inc (NASDAQ: ATNX) (before the market open)
Agile Therapeutics Inc (NASDAQ: AGRX) (after the close)
Atara Biotherapeutics Inc (NASDAQ: ATRA) (after the close)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) (after the close)
Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close)
Omeros Corporation (NASDAQ: OMER) (after the close)
ChemoCentryx Inc (NASDAQ: CCXI) (after the close)
FibroGen Inc (NASDAQ: FGEN) (after the close)
Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close)
Precigen Inc (NASDAQ: PGEN) (after the close)
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
Passage BioFebruary 19, 2021 GMT
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019.
“We are immensely excited to have Maxine join our board of directors,” said Dr. Bruce Goldsmith, president and chief executive officer of Passage Bio. “Her public company leadership and deep clinical development expertise will provide tremendous support to Passage Bio as we transition to a clinical development organization in the first half of 2021.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of .
Passage BioFebruary 8, 2021 GMT
- Phase 1/2 trial expected to commence in first half of 2021
- Company has three INDs cleared for rare monogenic CNS disorders
PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy being studied for the treatment of early infantile Krabbe disease (Globoid Cell Leukodystrophy). Currently, there are no approved disease-modifying therapies available for Krabbe disease, a rare lysosomal storage disease that most often
vimarsana © 2020. All Rights Reserved.